StockData

Acadia Pharmaceuticals vs Axsome Therapeutics

ACAD and AXSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACAD and AXSM compare

Axsome Therapeutics is the larger company, worth 2.3 times as much as Acadia Pharmaceuticals ($7.1B against $3.2B).

Axsome Therapeutics grew revenue faster over the last twelve months (56.9% versus 11.8% for Acadia Pharmaceuticals).

Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with −24.7% at Axsome Therapeutics.

Acadia Pharmaceuticals scores higher on the StockData Score (16 against 8 for Axsome Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACADAXSM
Size and price
Market cap$3.2B$7.1B
Share price$18.32$135.95
Change, 1 year−23.7%−2.7%
Change, 5 years−2.5%268%
Beta (5Y)0.530.87
Employees798500
StockData Score
Total score16 (better)8
Valuation score4 (better)0
Growth score23 (better)
Performance score4 (better)2
Health score6 (better)3
Dividend score00
Valuation
P/E8.3×–
P/S2.8× (better)9.2×
P/B2.4× (better)85.5×
EV/EBITDA25.5×–
P/FCF21.7×–
FCF yield4.6% (better)−1.0%
Fair value$25.26–
Margin of safety27.5%–
Growth
Revenue growth (TTM)11.8%56.9% (better)
Revenue growth, 5Y average19.4%–
Net income growth (TTM)71.3%–
EPS growth (TTM)66.2%–
Profitability
Gross margin91.1%93.2% (better)
Operating margin7.6% (better)−24.0%
Net margin33.4% (better)−24.7%
FCF margin12.8% (better)−9.3%
Return on equity35.7% (better)−245%
Return on invested capital42.1%–
Financial health
Debt / equity0.002.26 (better)
Current ratio3.39 (better)1.43
Altman Z-score4.32 (better)4.21
Piotroski F-score6 (better)5
Dividends and buybacks
Buyback yield−1.5%−0.50% (better)
Shareholder yield−1.5%−0.50% (better)
Ownership
Held by institutions97.9%73.8%
Held by insiders27.8%15.2%
Insider net buying, 12 months−$2.5M (better)−$113M
Short interest, % of float6.7%7.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.